
AbbVie ABBV
$ 210.58
2.04%
Annual report 2025
added 02-20-2026
AbbVie Cash Conversion Cycle 2011-2026 | ABBV
Annual Cash Conversion Cycle AbbVie
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 284 | 89.3 | 84.7 | 76.1 | 74.4 | 73.3 | 77.3 | 62.8 | 72.6 | 70.1 | 85.4 | 98.5 | 111 | 129 | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 284 | 62.8 | 99.1 |
Quarterly Cash Conversion Cycle AbbVie
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 159 | 174 | 184 | 167 | 167 | 178 | 132 | 160 | 170 | - | 61.9 | 71.7 | 112 | 59 | 128 | 131 | 111 | 58.1 | 122 | 159 | 162 | 56.9 | 145 | 151 | 113 | 59.2 | 139 | 135 | 101 | 60 | 157 | 66.9 | 68.7 | 65.5 | 69.2 | 67.3 | 72.7 | 66.3 | 71.4 | 78.8 | 76.6 | 62.5 | 67.9 | 69.2 | 75.9 | 68.8 | 75.5 | 75 | 85.9 | 75.3 | 87 | 87.3 | 47 | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 184 | 47 | 103 |
Cash Conversion Cycle of other stocks in the Biotechnology industry
| Issuer | Cash Conversion Cycle | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
ACADIA Pharmaceuticals
ACAD
|
257 | $ 22.5 | 1.86 % | $ 3.73 B | ||
|
Acorda Therapeutics
ACOR
|
117 | - | -24.86 % | $ 820 K | ||
|
Alnylam Pharmaceuticals
ALNY
|
46.6 | $ 327.16 | 2.39 % | $ 42.9 B | ||
|
Amgen
AMGN
|
217 | $ 349.22 | 2.71 % | $ 188 B | ||
|
Amphastar Pharmaceuticals
AMPH
|
205 | $ 20.4 | -0.87 % | $ 954 M | ||
|
I-Mab
IMAB
|
-1.97 K | - | - | $ 866 M | ||
|
Aquestive Therapeutics
AQST
|
-172 | $ 4.18 | 1.33 % | $ 447 M | ||
|
Alexion Pharmaceuticals, Inc.
ALXN
|
12.8 | - | - | $ 40.3 B | ||
|
Arcutis Biotherapeutics
ARQT
|
158 | $ 24.57 | 5.59 % | $ 3.13 B | ||
|
Ayala Pharmaceuticals
AYLA
|
-2.15 K | - | - | $ 7.46 M | ||
|
AstraZeneca PLC
AZN
|
-58 | - | - | $ 96.9 B | ||
|
Midatech Pharma plc
MTP
|
82.8 | - | -18.52 % | $ 27.3 M | ||
|
EyeGate Pharmaceuticals, Inc.
EYEG
|
17 | - | -1.52 % | $ 24.7 M | ||
|
Autolus Therapeutics plc
AUTL
|
119 | $ 1.48 | 8.46 % | $ 394 M | ||
|
BeiGene, Ltd.
BGNE
|
52.6 | - | 0.49 % | $ 251 B | ||
|
Advaxis
ADXS
|
-143 K | - | -9.65 % | $ 45.9 M | ||
|
Aytu BioScience
AYTU
|
174 | $ 2.71 | 5.51 % | $ 17 M | ||
|
Avid Bioservices
CDMO
|
85.5 | - | - | $ 789 M | ||
|
Cidara Therapeutics
CDTX
|
2.26 K | - | - | $ 1.41 B | ||
|
Институт стволовых клеток человека
ISKJ
|
104 | - | - | - | ||
|
Cerus Corporation
CERS
|
47 | $ 1.9 | 2.99 % | $ 362 M | ||
|
Coherus BioSciences
CHRS
|
149 | $ 1.7 | 1.8 % | $ 199 M | ||
|
CollPlant Biotechnologies Ltd.
CLGN
|
130 | $ 0.36 | 0.28 % | $ 4.12 M | ||
|
Aeterna Zentaris
AEZS
|
-34.3 K | - | 5.93 % | $ 314 M | ||
|
AgeX Therapeutics
AGE
|
186 | - | -10.17 % | $ 12.2 K | ||
|
Catalyst Pharmaceuticals
CPRX
|
120 | $ 25.57 | 2.3 % | $ 3.13 B | ||
|
CTI BioPharma Corp.
CTIC
|
-216 | - | - | $ 1.2 B | ||
|
AIkido Pharma
AIKI
|
-1.92 | - | 1.93 % | $ 17.4 M | ||
|
Cyclacel Pharmaceuticals
CYCCP
|
-1.6 K | - | -4.36 % | $ 27 M | ||
|
Deciphera Pharmaceuticals
DCPH
|
-101 | - | - | $ 2.18 B |